Abstract:12 Background: Penile squamous cell carcinoma (PSCC) is an infrequent yet progressively prevalent malignancy. Despite ongoing advancements in personalized and immunotherapeutic approaches, patients grappling with the diagnosis of locally advanced or metastasized PSCC still confront a limited therapeutic arsenal, leading to an unfavorable prognosis. Consequently, an imperative mandate arises to explore alternative therapeutic modalities, particularly antibody-drug-conjugates (ADCs), which have demonstrated significant clinical efficacy in the context of metastatic solid tumor pathologies. Our aim was to ascertain the potential utility of ADCs targeting Trop-2 in both localized PSCC (PRIM) and patient-matched distant metastases (MET). Methods: Immunohistochemical analysis of Trop-2 expression was conducted in PRIM ( N=40) and their corresponding METs ( N=9, including lymph node and lung metastases). We assessed overall survival (OS) by stratifying patients into subgroups based on Trop-2 expression: weak (H-score 15-99) versus moderate/strong (H-score 100-300). Additionally, we explored the relationship between Trop-2 and HPV-dependency. Furthermore, Trop-2 mRNA expression levels were quantified via qRT-PCR, and an enzyme-linked immunosorbent assay was employed to measure Trop-2 in serum samples derived from PRIM ( N=40) and a healthy control group ( N=10). Results: We found a statistically significant increase in Trop-2 mRNA expression levels in individuals afflicted with PSCC compared to healthy controls ( p<0.0001). Moreover, a notable elevation in Trop-2 protein expression was observed in the serum specimens obtained from PSCC patients ( p<0.01). The majority of patients exhibited moderate to strong Trop-2 expression, indicative of a robust median H-score of 280 (interquartile range: 210-300). Subgroup analysis revealed a correlation between Trop-2 expression and HPV status ( p<0.01), demonstrating discernible associations with more favorable clinical outcomes, as evidenced by the log-rank (Mantel-Cox) test ( p<0.05). Conclusions: Trop-2 protein expression in PSCC holds prognostic significance. Furthermore, the elevated Trop-2 levels in both PRIM and PSCC metastases suggest that the Trop-2-targeted ADC, Sacituzumab govitecan, may emerge as a promising novel therapeutic intervention for these patients.

The Role of TROP-2 in the Progression and Target Therapy in Penile Squamous Cell Carcinoma.

Trop-2: A promising new therapeutic target in penile squamous cell carcinoma.

TROP2 Expression and Therapeutic Implications in Cutaneous Squamous Cell Carcinoma: Insights From Immunohistochemical and Functional Analysis

Trophoblast cell surface antigen‐2: a promising new biomarker and potential therapeutic target in penile squamous cell carcinoma

Targeting Trop-2 in Cancer: Recent Research Progress and Clinical Application

Data from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer

Recent Advances in Trophoblast Cell-Surface Antigen 2 Targeted Therapy for Solid Tumors

Clinical impact of TROP2 in non-small lung cancers and its correlation with abnormal p53 nuclear accumulation

Trop2-targeted therapy in breast cancer

TROP2 in colorectal carcinoma: associations with histopathology, molecular phenotype, and patient prognosis

Trophoblast Cell-Surface Antigen 2 is a Biomarker and Potential Therapeutic Target in Human Colon Cancer.

Trop2-targeted therapies in solid tumors: advances and future directions

Progress and Innovative Combination Therapies in Trop-2-Targeted ADCs

Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer.

The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer.

The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target

Targeting Trop2 in solid tumors: a look into structures and novel epitopes

Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma.

Impact of Spatially Heterogeneous Trop-2 Expression on Prognosis in Oral Squamous Cell Carcinoma

Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer

Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors